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Summary 
Background Sepsis is one of the most common causes of neonatal deaths globally. Most sepsis-related deaths occur in 
low-income and middle-income countries, where the epidemiology of neonatal sepsis remains poorly understood. 
Most of these countries lack proper surveillance networks, hampering accurate assessment of the burden of sepsis, 
implementation of preventive measures, and investment in research. We report results of neonates born in hospital 
from a multicentre collaboration on neonatal sepsis. 
Methods In this cohort study, dedicated research teams prospectively followed up neonates born in one of three 
tertiary care centres in Delhi, India (Vardhaman Mahavir Medical College, Maulana Azad Medical College, and All 
India Institute of Medical Sciences [coordinating centre]) and subsequently admitted to the intensive care unit. 
Neonates were followed up daily until discharge or death. On clinical suspicion, neonates underwent sepsis work-up 
including blood cultures. The isolated organisms were identiﬁ ed and tested for antimicrobial susceptibility. We 
deﬁ ned Gram-negative isolates resistant to any three of ﬁ ve antibiotic classes (extended-spectrum cephalosporins, 
carbapenems, aminoglycosides, ﬂ uoroquinolones, and piperacillin-tazobactam) as multidrug resistant. 
Findings 13 530 neonates of 88 636 livebirths were enrolled between July 18, 2011, and Feb 28, 2014. The incidence of 
total sepsis was 14·3% (95% CI 13·8–14·9) and of culture-positive sepsis was 6·2% (5·8–6·6). Nearly two-thirds of 
total episodes occurred at or before 72 h of life (deﬁ ned as early onset; 1351 [83%] of 1980). Two-thirds (645 [64%]) 
of 1005 isolates were Gram-negative including, Acinetobacter spp (22%), Klebsiella spp (17%), and Escherichia coli (14%). 
The pathogen mix in early-onset sepsis did not diﬀ er from that of late-onset sepsis (ie, after 72 h). High rates of 
multidrug resistance were observed in Acinetobacter spp (181/222, 82%), Klebsiella spp (91/169, 54%), and Escherichia coli 
(52/137, 38%) isolates. Meticillin resistance prevailed in 61% (85/140) of coagulase-negative staphylococci and 38% 
(43/114) of Staphylococcus aureus isolates. Nearly a quarter of the deaths were attributable to sepsis. The population-
attributable risks of mortality were 8·6% in culture-negative sepsis, 15·7% in culture-positive sepsis by multidrug-
resistant organisms, and 12·0% in culture-positive sepsis by non-multidrug-resistant organisms.
Interpretation The high incidence of sepsis and alarming degree of antimicrobial resistance among pathogens in 
neonates born in tertiary hospitals underscore the need to understand the pathogenesis of early-onset sepsis and to 
devise measures to prevent it in low-income and middle-income countries.
Funding Indian Council of Medical Research.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction 
Sepsis is one of the three most common causes of neonatal 
deaths globally.1 Most infection-related deaths in the 
neonatal period occur in low-income and middle-income 
countries due to poor hygiene and suboptimal practices 
for infection control. A signiﬁ cant proportion of these 
deaths are caused by multidrug-resistant pathogens.2 
Despite the massive burden, few high-quality data about 
neonatal sepsis are available from these countries.2,3 
The currently available multisite studies on sepsis are 
from well-established surveillance networks in high-
income countries such as the USA, 4 the UK, 5 and 
Germany .6 Such infection surveillance networks are a 
rarity in low-income and middle-income countries;3 the 
few available ones have used passive surveillance (eg, the 
National Neonatal Perinatal Database [NNPD]7 and the 
Asia-Paciﬁ c Neonatal Infections Study [APNIS]8). Most of 
the other studies from low-income and middle-income 
countries are typically from a single site, retrospective, or 
have relied on routine laboratory reports. 9–12 They often 
lack rigorous data collection and reporting methods, and 
run the risk of misclassiﬁ cation and underestimation or 
overestimation of the incidence of sepsis. 13–15 
The paucity of high-quality data has undermined the 
recognition of neonatal sepsis as an area of serious 
concern in public health, the implementation of 
measures aimed at improvement of health-systems,3,13,14 
and investments in research and innovation in 
low-income and middle-income countries.14 In this study, 
we report data for incidence, proﬁ le of organisms, and 
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antimicrobial resistance from a prospective cohort study 
involving three major hospitals in Delhi, India. 
Methods 
Study design and participants 
The Delhi Neonatal Infection Study (DeNIS) collaboration 
comprises investigators at three tertiary care neonatal units: 
Vardhaman Mahavir Medical College (VMMC), Maulana 
Azad Medical College (MAMC), and All India Institute of 
Medical Sciences (AIIMS; coordinating centre), and one 
extramural neonatal unit (Chacha Nehru Bal Chikitsalaya) 
in Delhi. This descriptive cohort study was done among 
neonates delivered in the tertiary care hospitals (data for 
Chacha Nehru will be reported separately; appendix p 3) 
and who required admission to the neonatal intensive care 
unit (NICU) for any indication during the study period. 
Neonates requiring rehospitalisation after initial discharge 
were excluded. The research staﬀ  tracked all NICU 
admissions and enrolled neonates after obtaining informed 
consent from parents. The research staﬀ  prospectively 
recorded potential maternal risk factors at birth and 
neonatal factors on a daily basis until discharge or death of 
the neonates (appendix pp 20–21). 
The study was approved by the Institutional Ethics 
Committees of AIIMS, VMMC, and MAMC. Written 
informed consent was taken from the parents of enrolled 
neonates. 
Procedures 
All enrolled neonates were monitored daily for signs and 
symptoms of sepsis. Sepsis was suspected in the 
presence of perinatal risk factors or a set of clinical signs 
as per the Young Infant Study Algorithm.16 The research 
nurses obtained blood and, if needed, cerebrospinal ﬂ uid 
samples under strict aseptic conditions and sent them 
for culture and sepsis screen (appendix p 6) before 
initiation of any antibiotic therapy. Lumbar puncture was 
done in all cases of suspected sepsis at one site and only 
when suspected of meningitis at the other two sites.
The clinical team initiated antibiotics according to the 
policy of each unit (appendix p 3). The research nurses 
recorded the age at suspicion of sepsis, investigations 
done, details of the antibiotics administered, and the 
clinical course of the baby on a daily basis. 
Samples of blood and other body ﬂ uids were 
subcultured after overnight incubation in 5% sheep 
blood agar (BioMerieux, Marcy l’Etoile, France) and 
McConkey agar (Oxoid, Hampshire, UK; appendix p 22). 
Antimicrobial resistance of the isolates was determined 
as per Clinical and Laboratory Standards Institute 
guidelines (2011–13).17–19 Antimicrobial resistance was 
reported as susceptible, intermediate, resistant, or not 
tested for each individual antibiotic. Additionally, the 
Gram-negative pathogens were classiﬁ ed based on their 
resistance (intermediate or resistant) to various antibiotic 
Research in context
Evidence before this study
We searched PubMed using the terms “sepsis” and “neonate” 
(from Jan 1, 2005 to Feb 29, 2016), and limited the search to 
studies from low-income and middle-income countries. Of the 
1460 citations, we included 29 studies reporting data on 
predominantly (50% or more) neonates born in hospital, and 
had included at least 20 neonates with sepsis. We excluded 
studies with a community setting and those reporting data on 
only single organisms. Most studies were from a single centre 
(26) and had reported routine microbiology and clinical data 
(27). Generally, the quality of studies was low. The median 
number of neonates with sepsis was 84 (IQR 50–143). 
The incidence of culture-positive sepsis varied from 3·0 per 
1000 livebirths to 54·9 per 1000 livebirths (six studies) and case 
fatality rate varied from 9% to 30% (7 studies). The proportion 
of early-onset sepsis (onset within 2–4 days after birth; 
seven studies) ranged from 10·4% to 85·0% of total neonatal 
sepsis. On enlisting the three most common pathogens in each 
study, we found Klebsiella spp (15 studies), E coli (10 studies), 
and Staphylococcus aureus (ten studies) to be the common 
isolates.  Acinetobacter spp and group B streptococci were 
reported as one of three common pathogens in two and ﬁ ve 
studies, respectively. Pathogen proﬁ les were similar between 
early-onset and late-onset sepsis (ten studies). The three 
Gram-negative pathogens—Klebsiella spp, E coli, and 
Acinetobacter spp—showed a high degree of resistance to 
commonly used antibiotics such as ampicillin (up to 100%, 
100%, and 80%, respectively), cefotaxime (95%, 86%, and 
75%), and gentamicin (91%, 79%, and 100%). Carbapenem 
resistance was reported in Acinetobacter spp (0–30%; four 
studies) and E coli (0–15%; four studies); of the ﬁ ve studies 
reporting data for carbapenem resistance in Klebsiella spp, 
none showed resistance to carbapenems.
Added value of this study
Our study ﬁ lls a substantial signiﬁ cant gap in the 
understanding of epidemiology of sepsis in neonates in low-
income and middle-income countries. We report a high burden 
of sepsis among neonates born in tertiary hospitals. Almost 
two-thirds of sepsis episodes occurred at or before 72 h of life 
and were caused by pathogens usually associated with 
nosocomial infections. Acinetobacter spp emerged as the most 
common pathogen. There was a high degree of antimicrobial 
resistance even to reserve antibiotics such as carbapenems. 
Approximately half of culture positive neonates died due to 
sepsis and a quarter of all the deaths were attributable to 
sepsis.
Implications of all the available evidence
The ﬁ ndings underscore the need to examine the disease 
biology of early-onset sepsis, including its association with 
obstetric and neonatal care practices around birth, and to 
design relevant strategies to prevent infections.
See Online for appendix
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classes: extended-spectrum cephalosporins (any two of 
ceftazidime, ceftriaxone, or cefotaxime); carbapenems 
(imipenem or meropenem); aminoglycosides (any one of 
gentamicin, amikacin, or netilmicin); ﬂ uoroquinolones 
(ciproﬂ oxacin); and piperacillin–tazobactam. In the 
absence of universally accepted criteria, we deﬁ ned 
multidrug resistance as resistance to any three of these 
ﬁ ve antibiotic classes (adapted from Sievert and 
colleagues20). 
Two paediatricians prospectively assigned the diagnosis 
of sepsis for each suspected episode after reviewing the 
clinical course, sepsis screen, and culture reports. We 
used standard deﬁ nitions of sepsis, adapted from National 
Healthcare Safety Network (panel, appendix pp 4–5).21 
Data management and quality assurance 
The research staﬀ  at each site checked the case record 
forms daily for accuracy and completion, and the site 
investigators cross-checked the data weekly. Data were 
entered in duplicate in an online database developed in 
Visual Basics as front-end and MS SQL server as back-
end with inbuilt range and logical checks. 
We put in place a detailed quality assurance system for 
clinical and laboratory procedures, and data management 
system (appendix p 7). Detailed standard operating 
procedures were developed for key processes (abridged 
versions provided in the appendix pp 20–23). A dry run 
was carried out for 4 weeks before ﬁ nalising the case 
record forms and standard operating procedures. The 
case record forms were cross-checked by the faculty 
investigators at the sites as well as at the coordinating 
centre on a regular basis. Microbiology laboratories used 
specially procured high-quality culture media and 
antibiotic disks. Antibiotic disk batches were cross-
checked using ATCC strains. As a part of an external 
quality assurance scheme, the identiﬁ cation and 
antimicrobial resistance pattern of 10% of isolates were 
cross-checked at a diﬀ erent participating site. 
Statistical analysis 
We calculated the incidence of sepsis by dividing the 
number of neonates with sepsis by the total number of 
NICU admissions; 95% CIs were calculated using the cii 
command in Stata. The incidence density was calculated 
as the number of episodes of sepsis per 1000 patient-days 
or 1000 device-days. Population-attributable risk of 
mortality for diﬀ erent categories of sepsis was estimated 
by using the command csi in Stata. Statistical analysis 
was done with Stata 11.2. 
Role of the funding source 
The scientists of the Indian Council of Medical Research 
provided valuable inputs in protocol development and 
data analysis, and reviewed the ﬁ nal manuscript. The 
corresponding authors have full access to all the data in 
the study and take ﬁ nal responsibility for the decision to 
submit for publication.
Results
88 636 livebirths occurred from July 18, 2011, to Feb 28, 
2014. 14 779 (16·7%) neonates required NICU admission. 
After excluding 1249 neonates who were recruited in a 
concurrent trial, 13 530 (90·0%) were enrolled in the 
study (9239, 2657, and 1634 at the three sites; ﬁ gure 1). 
The mean birthweight of enrolled neonates was 2211 g 
(SD 741), and mean gestation was 36·0 weeks (SD 3·4; 
table 1, appendix p 8). Approximately two-thirds of 
neonates (8111, 59·9%) were low birthweight, and nearly 
half (5989, 44·2%) were preterm. A third of enrolled 
neonates (4708, 34·8%) were born by caesarean section. 
Although about a quarter (3170, 23·4%) of the mothers 
received antibiotics within 7 days before delivery, only a 
small proportion (587, 4·3%) received antibiotics for 48 h 
or more.  
4650 episodes of sepsis were suspected and 7131 cultures 
were done in 4408 neonates. A ﬁ nal diagnosis of sepsis 
was assigned in 1980 episodes (1934 neonates). The 
incidence of total sepsis was 14·3% (95% CI 13·8–14·9) 
and that of culture-positive sepsis was 6·2% (5·8–6·6; 
table 2, appendix p 6) of NICU admissions. The incidence 
density of total and culture-positive sepsis was 24·6 (95% 
CI 23·6–25·7) and 10·5 (9·8–11·3) per 1000 patient-days, 
respectively (table 2, appendix p 10). In terms of livebirths, 
the incidence of total and culture-positive sepsis was 21·8 
Panel: Deﬁ nitions used in the study
Culture-positive sepsis 
Isolation of a recognised pathogen from blood, cerebrospinal ﬂ uid, or other body ﬂ uids in 
neonates suspected to have sepsis on the basis of clinical features or maternal or perinatal 
risk factors, along with treatment involving appropriate type and duration of antibiotic 
therapy. Cases of sepsis with positive culture for coagulase-negative staphylococci were 
labelled only if the clinical course was suggestive of sepsis and appropriate antibiotic 
therapy was given.
Culture-negative sepsis 
Clinical course suggestive of sepsis or positive sepsis screen, but no pathogen isolated or 
blood culture not done.
Total sepsis
Number of neonates with culture positive sepsis or culture negative sepsis.
Early-onset sepsis
Occurrence of sepsis at or before 72 h of life.
Late-onset sepsis 
Occurrence of sepsis after 72 h of life. 
Central-line-associated bloodstream infection 
Having a central line (umbilical or non-umbilical) for more than 2 calendar days before the 
day of onset of blood culture-positive sepsis. 
Meningitis 
Positive cerebrospinal ﬂ uid culture, Gram staining, or neutrophilic leucocytosis, with or 
without low sugar (less than 50% of plasma glucose level) and high protein content.
Detailed deﬁ nitions are provided in the appendix.
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and 9·5 per 1000 livebirths, respectively. Meningitis was 
detected in 200 (1·5%) neonates, whereas central-line-
associated bloodstream infection was diagnosed in 
44 episodes of sepsis (9·9 per 1000 central-line days). 
1351 (68·2%) of 1980 sepsis episodes—more than two-
thirds—were early onset. The incidence of total and 
culture-positive sepsis varied among the study sites, 
ranging from 11·9% to 18·9% for total sepsis and 3·6% to 
10·5% for culture-positive sepsis (table 2). 
Of the total 1005 isolates, about two-thirds were Gram-
negative pathogens, the most common being Acinetobacter 
spp, Klebsiella spp, Escherichia coli, Pseudomonas spp, and 
Enterobacter spp (table 3). The predominant Gram-positive 
pathogens were coagulase-negative staphylococcus, 
Staphylococcus aureus, and Enterococcus spp. Group B 
streptococci were isolated in only a few neonates. The 
case fatality rate in neonates with sepsis due to Gram-
negative pathogens was higher than that of neonates 
infected with Gram-positive pathogens (59% vs 33%). 
Neonates infected with Pseudomonas spp had the highest 
case fatality rate (table 3). 
The pathogen mix in early-onset sepsis did not diﬀ er 
much from that of late-onset sepsis (ie, sepsis after 72 h; 
appendix p 13). The relative proportion of each pathogen 
isolated on diﬀ erent days of life was similar (ﬁ gure 2). 
The proﬁ le of isolates showed substantial variation 
among the three study sites: the most common isolate 
was Acinetobacter spp (155/576, 27%) in the ﬁ rst site, 
Klebsiella spp (89/359, 25%) in the second site, and 
coagulase-negative staphylococcus (32/70, 46%) in the 
third site (appendix p 14). 
Most isolated pathogens showed a high degree of 
antimicrobial resistance, not only to commonly used 
antibiotics but also to so-called reserve antibiotics such as 
extended-spectrum cephalosporins and carbapenems 
(table 4, appendix p 15). A high proportion of Acinetobacter 
spp (181/222, 82%), Klebsiella spp (91/169, 54%), and 
E coli (52/139, 38%) was multidrug resistant. Colistin 
resistance was detected in seven (1%) Gram-negative 
isolates. Among Gram-positive pathogens, meticillin 
resistance was detected in 61% (85/140) of coagulase-
negative staphylococci and 38% (43/114) of S aureus. All 
the isolates of coagulase-negative staphylococci and 
Staphylococcus aureus were susceptible to vancomycin, 
but about a quarter of enterococci isolates (13/46, 27%) 
were resistant. The case fatality rate of sepsis caused by 
resistant pathogens was only slightly higher than that of 
sepsis caused by sensitive isolates (table 4).
Figure 1: Study ﬂ ow
NICU=neonatal intensive care unit. NEC=necrotising enterocolitis. *Refers to 
number of cultures done and not the number of neonates. †Not mutually 
exclusive categories. 
88 636 livebirths
14 779 admitted to NICU
13 530 recruited
1249 enrolled in another study
9122 no clinical suspicion of sepsis
4408 assessed for infection 
(4650 episodes)
5849 blood culture*
1249 CSF culture*
4534 sepsis screen*
33 others*
2417 died, were referred, or left 
against medical advice
1934 diagnosed with 
sepsis syndromes†
840 culture-positive sepsis
1094 culture-negatove sepsis
200 meningitis
38 NEC
8 others
Number of neonates 
(n=13 530)
Neonatal variables
Birthweight, g 2211 (741)
Gestation, weeks 36·0 (3·4)
Small for gestation 3641 (26·9%)
Sex
Boys 7678 (56·7%)
Girls 5852 (43·3%)
Multiple births 1493 (11·0%)
Caesarean delivery 4703 (34·8%)
Major malformations 804 (5·9%)
Positive-pressure ventilation 4187 (30·9%)
Maternal and perinatal variables
Antenatal corticosteroids 3970/4900 (81·0%)* 
Maternal fever within 7 days before delivery 1057 (7·8%)
Maternal antibiotics within 7 days before delivery 3170 (23·4%)
Received for 48 h or more 587 (4·3%)
Per-vaginal examination (≥3) 5209 (38·5%)
Prolonged rupture of membranes (18 h or more) 1958 (14·5%)
Prolonged labour (24 h or more) 173 (1·3%)
Meconium-stained liquor 3073 (22·7%)
Foul-smelling liquor 374 (2·8%)
Neonatal care-related variables
Intravenous ﬂ uids 8928 (66·0%)
Parenteral nutrition 272 (2·0%)
Peripheral arterial line 449 (3·3%)
Any central line 835 (6·2%)
Continuous positive airway pressure 2746 (20·3%)
Mechanical ventilation 1619 (12·0%)
Jaundice requiring phototherapy 3402 (25·1%)
Duration of NICU stay, days 2·7 (1·3–5·5)
Data are mean (SD), median (IQR), or n (%). NICU=neonatal intensive care unit. 
*Only in neonates below 35 weeks’ gestation. 
Table 1: Demographic details of enrolled neonates
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Sepsis was the underlying cause of death in nearly a 
quarter (505/2106, 24%) of neonates (appendix p 17). The 
case fatality rate was 26% (496/1934) for all sepsis cases 
and 48% (400/840) for culture-positive sepsis cases 
(table 2, appendix p 18). Case fatality rates did not diﬀ er 
between early-onset sepsis (324/1351  [24%] for total 
sepsis, 258/525 [49%] for culture-positive sepsis) and 
late-onset sepsis (172/583 [29·5%] and 142/315 [45%], 
respectively). The attributable risks of mortality were 
88·6% in culture-negative sepsis, 97·3% in culture-
positive sepsis by multidrug-resistant organisms, and 
96·9% in culture-positive sepsis by non-multidrug-
resistant organisms; the corresponding population-
attributable risks were 8·6%, 15·7%, and 12·0%, 
respectively (table 5, appendix p 19). 
Discussion 
In this large, multisite cohort study, we record a high 
incidence and case fatality rate of sepsis, accounting for 
nearly a quarter of deaths in neonates born in tertiary 
neonatal units in Delhi. Most infections occurred early, 
and Acinetobacter spp emerged as the predominant 
causative organisms. Most pathogens showed an 
alarming degree of antimicrobial resistance. 
This study deserves attention for three major reasons. 
First, with more than 80 000 livebirths and 
13 500 enrolled neonates, our ﬁ ndings ﬁ ll a substantial 
gap in the understanding of the epidemiology of 
neonatal sepsis in low-income and middle-income 
countries.22,23 Second, the data generated are not a 
byproduct of a passive surveillance as in previous 
studies (eg, the International Nosocomial Infection 
Control Consortium [INICC],24 APNIS,8 NNPD,7 and 
others) but reﬂ ect ﬁ ndings of a prospective study with a 
high degree of methodological rigour. Third, the results 
would help policy makers to estimate the burden and 
possible eﬀ ect of interventions to reduce sepsis-related 
mortality. The most important ﬁ ndings of our study 
include early occurrence of sepsis (most episodes 
occurring at or before 72 h of life), identiﬁ cation of 
classic late-onset nosocomial pathogens (rather than 
those typically acquired from the mother) causing 
early-onset sepsis, Acinetobacter spp emerging as 
the dominant pathogen, and an alarming degree of 
antimicrobial resistance to even reserve antibiotics.
Most episodes of sepsis occurred at a quite early age, 
with nearly a quarter of culture-positive sepsis episodes 
occurring within 24 h of birth and two-thirds within 
72 h. This pattern is in sharp contrast with that reported 
Total sepsis Culture-positive sepsis Culture-negative sepsis Meningitis
Incidence*
Overall (n=13 530) 1934 (14·3%; 13·8–14·9) 840 (6·2%; 5·8–6·6) 1094 (8·1%; 7·6–8·6) 200 (1·5%; 1·3–1·7)
Site 1 (n=9239) 1237 (13·4%; 12·7–14·1) 502 (5·4%; 5·0–5·9) 735 (8·0%; 7·4–8·5) 119 (1·3%; 1·1–1·5)
Site 2 (n=2657) 502 (18·9%; 17·4–20·4) 279 (10·5%; 9·4–11·7) 223 (8·4%; 7·4–9·5) 67 (2·5%; 1·9–3·2)
Site 3 (n=1634) 195 (11·9%; 10·4–13·6) 59 (3·6%; 2·7–4·6) 136 (8·3%; 7·0–9·8) 14 (0·9% 0·5–1·4)
Incidence density†
Overall (n=80 427) 1980 (24·6; 23·6–25·7) 847 (10·5; 9·8–11·3) 1133 (14·1; 13·3–14·9) 200 (2·5; 2·2–2·8)
Site 1 (n=42 419) 1246 (29·4; 27·8–31·0) 502 (11·8; 10·8–12·9) 744 (17·5; 16·3–18·8) 119 (2·8; 2·3–3·3)
Site 2 (n=21 342) 517 (24·2; 22·2–26·4) 281 (13·2; 11·7–14·8) 236 (11·1; 9·7–12·5) 64 (3·0; 2·3–3·8)
Site 3 (n=16 666) 217 (13·0; 11·3–14·8) 64 (3·8; 2·9–4·9) 153 (9·2; 7·8–10·7) 14 (0·8; 0·4–1·4)
Case fatality rate‡
Overall 496/1934 (25·6%; 23·7–27·7) 400/840 (47·6%; 44·2–51·0) 96/1094 (8·8%; 7·2–10·6) 102/200 (51·0%; 43·8–58·1)
Site 1 248/1237 (20·0%; 17·8–22·4) 200/502 (39·8%; 35·5–44·3) 48/735 (6·5%; 4·8–8·6) 45/119 (37·8%; 29·1–47·2)
Site 2 226/502 (45·0%; 40·6–49·5) 188/279 (67·4%; 61·5–72·8) 38/223 (17·0%; 12·3–22·6) 56/67 (83·6%; 72·5–91·5)
Site 3 22/195 (11·3%; 7·2–16·6) 12/59 (20·3%; 11·0–32·8) 10/136 (10·4%; 3·6–13·1) 1/14 (7·1 %; 0·2–33·8)
*Among those admitted to neonatal intensive care. Data are number of cases (%; 95% CI). †Data are number of episodes, (number of episodes per 1000 patient-days; 
95% CI). ‡Data are number of deaths/number of cases (%; 95% CI).
Table 2: Incidence and case fatality of neonatal sepsis
Number of 
isolates (n=1005)
Number of deaths 
(case fatality rate)
Gram negative
Acinetobacter spp 222 (22%) 130 (59%)
Klebsiella spp 169 (17%) 95 (56%)
Escherichia coli 137 (14%) 83 (61%)
Pseudomonas spp 68 (7%) 53 (78%)
Enterobacter spp 44 (4%) 16 (36%)
Gram positive
Coagulase-negative 
staphylococci
150 (15%) 40 (27%)
Staphylococcus aureus 122 (12%) 43 (35%)
Enterococcus spp 56 (6%) 33 (59%)
Group B streptococci 8 (1%) 5 (62%)
Others 29 (3%) 13 (45%)
Data are n (%). See appendix for further details on meningitis and central line 
associated bloodstream infection. 
Table 3: Proﬁ le of bacterial isolates and their case fatality rates 
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from high-income countries, where most infections 
occur after 72 h of life.5,25,26 Even studies from other 
Asian countries such as China 27 and Korea12 have shown 
a predominance of late-onset sepsis. Nearly half of 
neonates with culture-positive sepsis in our study died 
despite early detection and appropriate supportive care. 
This ﬁ nding probably does not result from high 
antimicrobial resistance, in view of the almost identical 
case fatality rates between multidrug-resistant and non-
multidrug-resistant pathogens (table 4). Unusually 
high virulence of pathogens could be one possible 
reason. Traditionally, the common pathogens im-
plicated in early-onset sepsis include E coli, group B 
streptococci, Listeria monocytogenes, and Enterococcus 
spp. The ﬁ ndings of our study, however, contrast with 
this notion as well as reports from high-income 
countries.5–7,14 Acinetobacter spp, coagulase-negative 
staphylococci, and Klebsiella spp, usually recognised as 
nosocomial pathogens, were the dominant pathogens 
even in neonates with early-onset sepsis. Group B 
streptococci were isolated rarely. Findings from a few 
other studies with smaller sample size from India have 
also shown similar results.9,28 The high rate of early-
onset sepsis and the apparent dominance of so-called 
nosocomial-type pathogens in early-onset sepsis could 
possibly be due to ultra-early horizontal transmission 
from delivery rooms and NICUs,13,14,29 or vertical 
transmission from the maternal genital tract colonised 
with these pathogens after unhygienic personal and 
obstetric practices. 30,31
Acinetobacter spp (22%) emerged as the most common 
isolates in our cohort. Although a few recent studies 
from India9,10,30,31 and other low-income and middle-
income countries did report it as one of the isolates,11,27,32 
none has so far reported such a degree of dominance. Of 
the 1248 isolates reported by the NNPD Network, 
Klebsiella spp (32%) were the leading pathogens, with the 
proportion of Acinetobacter spp being a low 3%.7 Are we 
witnessing a growing scourge of Acinetobacter spp 
infections in India’s tertiary neonatal units?31 In view of 
the high degree of antimicrobial resistance—including 
resistance to carbapenems (78·3%)—and the high case 
fatality rate (59%) in our cohort, the increasing burden of 
Acinetobacter sepsis might pose a formidable threat 
in coming years. Acinetobacter baumanii, the usual 
dominant species, is capable of rapid clonal expansion in 
face of selection pressure by broad-spectrum anti-
Figure 2: Proﬁ le of pathogens isolated on diﬀ erent days of life 
CoNS=coagulase-negative staphylococci.
Group B streptococci (n=8) Others (n=29) Enterobacter spp (n=44)
Enterococcus spp (n=56) Pseudomonas spp (n=68) S aureus (n=122) E coli (n=137)
CoNS (n=150) Klebsiella spp (n=169) Acinetobacter spp (n=222)
Day 1
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CFR in culture-
positive sepsis 
due to 
resistant 
pathogens
CFR in culture-
positive sepsis 
due to 
sensitive 
pathogens
Gram negative
Acinetobacter spp (n=222)
ES cephalosporins 85/222 (38%) 59/85 (69%) 71/137 (52%)
Carbapenems 174/222 (78%) 106/174 (61%) 24/48 (50%)
MDR 181/222 (82%) 112/181 (62%) 18/41 (44%)
Klebsiella spp (n=169)
ES cephalosporins 105/169 (62%) 57/104 (55%) 38/65 (58%)
Carbapenems 59/169 (35%) 36/59 (61%) 59/110 (54%)
MDR 91/169 (54%) 52/91 (57%) 43/78 (55%)
Escherichia coli (n=137)
ES cephalosporins 65/137 (47%) 40/64 (63%) 43/73 (59%)
Carbapenems 21/137 (15%) 12/21 (57%) 71/116 (61%)
MDR 52/137 (38%) 30/52 (58%) 53/85 (62%)
Pseudomonas spp (n=68)
ES cephalosporins 32/68 (47%) 29/32 (91%) 24/36 (67%)
Carbapenems 21/68 (31%) 19/21 (90%) 34/47 (72%)
MDR 13/68 (19%) 11/13 (85%) 42/55 (76%)
Enterobacter spp (n=44)
ES cephalosporins 20/44 (45%) 6/20 (30%) 10/24 (42%)
Carbapenems 9/ 44 (20%) 4/9 (44%) 12/35 (34%)
MDR 22/44 (50%) 8/22 (36%) 8/22 (36%)
Gram positive 
Coagulase-negative staphylococci (n=150)
Meticillin 85/140 (61%) 23/85 (27%) 14/55 (25%)
Vancomycin 0/138 ·· 36/138 (26%)
Staphylococcus aureus (n=122 )
Meticillin 43/114 (38%) 16/43(37%) 22/71 (31%)
Vancomycin 0/114 ·· 38/114 (33%)
Enterococcus spp (n=56)
Meticillin 11/14 (79%) 10/11 (91%) 2/3 (67%)
Vancomycin 13/48 (27%) 9/13 (69%) 20/35 (57%)
Data are n/N (%); there are variations in denominators in few cells as antibiotic 
sensitivity testing for all drugs was not done. CFR=case fatality rate. ES=extended-
spectrum. MDR=multidrug resistance (ie, I [intermediate] or R [resistant] to on 
drug in three of the following classes: ES cephalosporins, ﬂ uoroquinolones, 
aminoglycosides, carbapenems, and piperacillin-tazobactam).
 Table 4: Case fatality rates among common pathogens by their 
antimicrobial resistance pattern 
Articles
www.thelancet.com/lancetgh   Vol 4   October 2016 e758
biotics.33–35 This property might have led to its proliferation 
and subsequent dominance in our cohort after sporadic 
entry in the NICUs. Its endemicity is further facilitated 
by suboptimal infection control practices including 
inadequate hand hygiene compliance in low-income and 
middle-income settings.14,34,36
Our results are consistent with a high degree of 
antimicrobial resistance documented in other reports 
from India.9,30,37 The high prevalence of resistance to 
extended-spectrum cephalosporins, carbapenems, and 
the emerging resistance to colistin in the three most 
common Gram-negative isolates (Acinetobacter spp, 
Klebsiella spp, and E coli) make the choice of antibiotics 
extremely diﬃ  cult.  We used classes of higher-spectrum 
antibiotics (carbapenems, piperacillin–tazobactam) to 
deﬁ ne multidrug resistance rather than the WHO-
recommended ﬁ rst-line options such as ampicillin, 
gentamicin, and cefotaxime.8,29 Our deﬁ nition, therefore, 
includes the most severe form of multidrug resistance. 
The high rates of multidrug resistance (40–81%)—
despite such a rigorous deﬁ nition—in the three common 
Gram-negative bacteria threaten the return of 
preantibiotic era in Indian NICUs.5,37,38 This frequent 
multidrug resistance in common pathogens raises the 
possibility of cross-transmission of mobile genetic 
elements that are able to jump across genera, including 
commensals.39 In preliminary results from our network, 
the presence of NDM-1 has been documented in nearly a 
quarter of Acinetobacter spp and three-quarters of 
Klebsiella spp among the pool of carbapenem-resistant 
strains (data not shown). 
Although our antimicrobial resistance results are 
alarming, the more ominous ﬁ nding that has 
implications for policy makers is the risk of mortality 
attributable to culture-positive sepsis in general 
(table 5). The population-attributable risk in culture-
positive sepsis by multidrug-resistant organisms was 
only slightly higher than that of sepsis by non-
multidrug resistant organisms (15·7% vs 12·0%). If 
resistance to only aminoglycosides and cephalosporins 
(for Gram negative) or cefoxitin (for Gram-pos-
itive organisms) is considered, the corresponding 
population-attributable risk would be 11·8% for sepsis 
caused by resistant isolates and 15·8% for sepsis caused 
by sensitive isolates (appendix p 19). The high risk of 
mortality for sensitive isolates is puzzling, given that 
inappropriate choice of empirical antibiotics in the ﬁ rst 
48–72 h after suspicion of sepsis (ie, until culture 
reports are available) is unlikely to aﬀ ect mortality. The 
results call for a rethink among diﬀ erent stakeholders3,40 
to focus equally, if not more, on strategies to prevent 
sepsis by having a better understanding of the 
pathogenesis, along with addressing antimicrobial 
resistance in intensive care units from low-income and 
middle-income countries. 
 Our study has several limitations. First, there 
was considerable heterogeneity in infrastructure, 
manpower, practices, and patient proﬁ le, which might 
have masked interinstitutional diﬀ erences in epi-
demiology of sepsis. Second, we did not separately 
record pneumonia, including ventilator-associated 
pneumonia, because of practical diﬃ  culties. Third, we 
may have overestimated the incidence of coagulase-
negative staphylococci, because its diagnosis was not 
based on two simultaneous blood cultures. However, 
we followed stringent, protocol-driven practices for 
skin preparation before obtaining blood culture 
specimens, and the diagnosis of sepsis caused by 
coagulase-negative staphylococci was made only after 
detailed review of clinical course. Fourth, the incidence 
of sepsis (particularly late-onset sepsis) might have 
been underestimated because the neonates were not 
followed up after discharge from the hospital. 
Our study highlights the need to undertake research to 
understand the pathogenesis of early-onset sepsis and to 
devise measures to prevent related morbidity and 
mortality. The ﬁ ndings also serve as a yet another wake-
up call for global action to curb the escalating menace of 
antimicrobial resistance. 
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Died (n=2103) Survived 
(n=85 033)
Relative risk 
(95% CI)
Attributable risk 
percentage (95% CI)
Population-
attributable risk
No sepsis 1457 (69·3%) 83 817 (98·6%) 1·0 ·· ··
Culture-negative sepsis 158 (7·5%) 894 (1·0%) 8·79 (7·55–10·2) 88·6% (86·7–90·2) 8·6%
Culture-positive sepsis by sensitive organisms 
(MDR negative or cefoxitin sensitive)
207 (9·8%) 165 (0·2%) 32·6 (29·34–36·13) 96·9% (96·6–97·2) 12·0%
Culture-positive sepsis by resistant organisms 
(MDR positive or cefoxitin resistant)
281 (13·4%) 157 (0·2%) 37·5 (34·43–40·94) 97·3% (97·1–97·5) 15·7%
Resistance deﬁ ned as multidrug resistant (for Gram-negative organisms) or cefoxitin resistant (for Gram-positive organisms). For the purpose of calculating 
population-attributable risk, we used all livebirths as the denominator and assumed that the remaining neonates who did not get admitted to neonatal intensive care (and 
therefore not enrolled in the study) did not develop sepsis.
Table 5: Sepsis categories and their attributable and population-attributable risk of mortality
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